144656-11-1

Basic information

• Product Name: Glycine, N-(4-cyanophenyl)-, 1,1-dimethylethyl ester
• CAS NO: 144656-11-1
• Molecular Formula: C13H16N2O2
• Molecular Weight: 232.282
• Mol File: 144656-11-1.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Glycine, N-(4-cyanophenyl)-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Glycine, N-(4-cyanophenyl)-, 1,1-dimethylethyl ester(144656-11-1)
• EPA Substance Registry System: Glycine, N-(4-cyanophenyl)-, 1,1-dimethylethyl ester(144656-11-1)

Safety Data

• Hazardous Substances Data: 144656-11-1(Hazardous Substances Data)

Usage

General Description

Glycine, N-(4-cyanophenyl)-, 1,1-dimethylethyl ester, also known as tert-butyl N-(4-cyanophenyl)glycinate, is a chemical compound with the molecular formula C12H15NO2. It is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other fine chemicals. Glycine, N-(4-cyanophenyl)-, 1,1-dimethylethyl ester is a derivative of glycine, an essential amino acid, which plays a crucial role in the synthesis of protein and other biochemicals in the body. As a tert-butyl ester, it has a bulky and stable structure, making it a valuable building block in organic synthesis and drug discovery. The chemical is often handled and stored in a controlled environment due to its potential hazardous properties.

Upstream product

• 5292-43-3 bromoacetic acid tert-butyl ester 
• 873-74-5 4-Aminobenzonitrile 

Downstream Products

• 194162-76-0 7-[2-(4-Cyano-phenylamino)-acetylamino]-heptanoic acid tert-butyl ester 
• 42288-26-6 (4-cyanophenyl)glycine 

Relevant articles and documents

SUBSTITUTED PYRROLES AND METHODS OF USE

The invention relates to substituted pyrrole compounds of Formula (I) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chkl) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists

The use of 5,6-bicyclic amidines as arginine surrogates in the design of a novel class of potent platelet glycoprotein IIb-IIIa receptor (GPIIb-IIIa) antagonists is described. The additional conformational restriction offered by the bicyclic nucleus results in 20-400-fold increases in potency compared to the freely flexible, acyclic benzamidine counterpart. The design, synthesis, structure-activity relationships (SAR), and in vitro activity of this novel class of GPIIb-IIIa antagonists are presented.

Cyclic urea derivatives, pharmaceutical compositions containing these compounds and methods of using the same

The invention relates to cyclic urea derivatives of general formula STR1 wherein Ra, Rb, X and Y are as defined herein, pharmaceutical compositions containing the derivatives and processes for preparing them.